Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC33A1 | O00400 | 13/20 | 0.45 |
| ▸ | PPARG | P37231 | 5/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4304253 | 0.93 | SLC33A1 (0.44) | SLC33A1PPARGAGTR1 | |
| SCHEMBL1894858 | 0.92 | SLC33A1 (0.54) | SLC33A1PPARGAGTR1 | |
| SCHEMBL4304292 | 0.91 | SLC33A1 (0.45) | SLC33A1PPARGAGTR1 | |
| SCHEMBL1895671 | 0.91 | SLC33A1 (0.53) | SLC33A1PPARGAGTR1 | |
| SCHEMBL4317672 | 0.89 | PPARG (0.45) | SLC33A1PPARG | |
| SCHEMBL3486931 | 0.88 | SLC33A1 (0.47) | SLC33A1PPARG | |
| SCHEMBL1891428 | 0.87 | PPARG (0.52) | SLC33A1PPARGAGTR1 | |
| SCHEMBL4017629 | 0.86 | SLC33A1 (0.51) | SLC33A1PPARG | |
| SCHEMBL3487690 | 0.85 | SLC33A1 (0.43) | SLC33A1PPARG | |
| SCHEMBL4312291 | 0.85 | SLC33A1 (0.45) | SLC33A1PPARGAGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009133970-A1 | CRYSTALLINE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-11-05 | — | — | WO | disclosed |